Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:125094.
doi: 10.1155/2015/125094. Epub 2015 Mar 22.

MicroRNAs as potential biomarkers in cancer: opportunities and challenges

Huiyin Lan  1 , Haiqi Lu  2 , Xian Wang  2 , Hongchuan Jin  1
Affiliations
Review

MicroRNAs as potential biomarkers in cancer: opportunities and challenges

Huiyin Lan et al. Biomed Res Int. 2015.

Abstract

MicroRNAs (miRNAs) are a group of small noncoding RNAs (ncRNAs) that posttranscriptionally regulate gene expression by targeting their corresponding messenger RNAs (mRNAs). Dysregulated miRNAs have been considered as a new type of ''oncomiRs" or ''tumor suppressors," playing essential roles in cancer initiation and progression. Using genome-wide detection methods, ubiquitously aberrant expression profiles of miRNAs have been identified in a broad array of human cancers, showing great potential as novel diagnostic and prognostic biomarkers of cancer with high specificity and sensitivity. The detectable miRNAs in tissue, blood, and other body fluids with high stability provide an abundant source for miRNA-based biomarkers in human cancers. Despite the fact that an increasing number of potential miRNA biomarkers have been reported, the transition of miRNAs-based biomarkers from bench to bedside still necessitates addressing several challenges. In this review, we will summarize our current understanding of miRNAs as potential biomarkers in human cancers.

PubMed Disclaimer

References

    1. Atkinson A. J., Colburn W. A., DeGruttola V. G., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 2001;69(3):89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2095–2128. - PMC - PubMed
    1. Moyer V. A. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Annals of Internal Medicine. 2012;157(2):120–134. doi: 10.7326/0003-4819-157-2-201207170-00459. - DOI - PubMed
    1. Lee R. C., Feinbaum R. L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854. doi: 10.1016/0092-8674(93)90529-Y. - DOI - PubMed
    1. Kong Y. W., Ferland-McCollough D., Jackson T. J., Bushell M. microRNAs in cancer management. The Lancet Oncology. 2012;13(6):e249–e258. doi: 10.1016/S1470-2045(12)70073-6. - DOI - PubMed

Publication types